To read the full story, subscribe or sign in.

OncoGenex Bolsters Pipeline Work via $50M Public Offering

Oct. 20, 2010

OncoGenex Pharmaceuticals Inc. took advantage of a recent stock bump to boost its cash position via a $50 million public offering. (BioWorld Today)

BioWorld

Today's news in brief

BioWorld

BioWorld briefs for April 17, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for April 14, 2026

Elderly woman holding illustration of brain with missing puzzle piece

Meta-analysis: Anti-amyloid Alzheimer’s drugs not ‘clinically meaningful’

BioWorld

The ongoing controversy over the effectiveness of anti-amyloid drugs is about to get more heated, after a review of clinical trials showed statistically...

Selective CBL-B inhibitor with improved safety profile disclosed

BioWorld Science

CBL-B is a RING-type E3 ubiquitin ligase that acts as a negative regulator of T-cell activation, contributing to immune homeostasis by limiting excessive immune...

MSD discloses new HCN1/2 blockers

BioWorld Science

Merck Sharp & Dohme LLC (MSD) has synthesized new indazole derivatives acting as potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 1...